Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics (Nasdaq: WHWK) will participate in three investor conferences in early March 2026: TD Cowen, Leerink Global Healthcare, and Citizens Life Sciences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK) will participate in three investor conferences in early March 2026: TD Cowen, Leerink Global Healthcare, and Citizens Life Sciences. Presentations and investor meetings feature CEO Dave Lennon and other executives.
TD Cowen presentation and fireside chat: March 3, 10:30 AM ET. Leerink investor meetings: March 9. Citizens corporate presentation: March 10, 12:30 PM ET. A live webcast of TD Cowen and Citizens presentations will be available on the company's investor relations website and replayed for ~30 days.
Details
News Market Reaction – WHWK
On Feb 26, the day this news came out, WHWK closed 1.52% below the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- TD Cowen 46th Annual Health Care Conference – Dave Lennon, PhD, President and CEO, will participate in a hybrid presentation and fireside chat on Tuesday, March 3 at 10:30 AM ET
- Leerink 2026 Global Healthcare Conference – executives will participate in investor meetings on Monday, March 9
- Citizens Life Sciences Conference – Dave Lennon, PhD, President and CEO, will give a corporate presentation on Tuesday, March 10 at 12:30 PM ET
A live webcast of the TD Cowen and Citizens presentations can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences-302697787.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
